SEINE BIO · PEPTIDE PROFILE
Emideltide / DSIP
Sleep-related peptide research
ExperimentalGet to know the name, understand the evidence, and prepare a more informed conversation.
What is Emideltide / DSIP?
Delta sleep-inducing peptide has been explored in small, older sleep studies. Its name should not be read as proof of an effective insomnia treatment. FDA lacks route-specific safety information. FDA safety context.
THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026
Inside the science of Emideltide / DSIP.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is an option only where the particular substance, product, and prescribing pathway are lawful; a pharmacy cannot make every research compound available for patient use. Approved finished medicines may also be obtained from licensed non-compounding pharmacies.
Overview
DSIP stands for delta sleep-inducing peptide; emideltide is another name used for the substance. The name reflects an early research idea, not a guarantee that it improves deep sleep. Sleep regulation involves multiple systems, and an experimental peptide’s label should not be treated as proof of a therapeutic effect.
Community Use
PeptideDosages.com publishes DSIP protocol material. Community discussion often centers on sleep onset, restfulness, or recovery. Personal reports may generate questions, but they cannot separate treatment effects from changing sleep habits, expectation, fluctuating symptoms, or another intervention used at the same time.
Doses, Durations & Cycles
Informal biohacking protocols and published regimens. Attributed website reports for education, not medical recommendations. Multiple publications document circulation; they do not establish a safe dose or validate a cycle.
| Route / formulation | Dose / reported phases | Frequency | Duration / break | Notes and source |
|---|---|---|---|---|
| Subcutaneous | 250 mcg per administration. | Five evenings weekly, with two off evenings. | Eight weeks. Break: Eight weeks between courses, plus two off evenings weekly. | Published informal biohacking claim The Peptide Catalog |
| Subcutaneous | 100–300 mcg per administration. | Daily; the page also mentions some every-other-night use. | Four weeks. Break: Two weeks. | Published informal biohacking claim Pep-Tidy |
Important context: Schedules and breaks differ. The claims do not establish efficacy, an average dose or a safe maximum.
Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.
No FDA-approved DSIP insomnia dose or cycle is established. A small historical research series cannot validate a modern daily wellness schedule or a different preparation. The preserved chart should be read as an account of source claims, not a set of directions for managing a sleep disorder.
Research Findings
An open 1984 study involved seven people with severe insomnia. Six reportedly experienced normalized sleep after a series of administrations, with follow-up over several months. The tiny sample and lack of a control group make it impossible to attribute the outcome confidently to DSIP or predict typical benefit.
U.S. Approval & Access
DSIP is not FDA-approved. Historical research does not create routine US availability for insomnia treatment. Ask whether any proposed product has an authorized clinical or research pathway and appropriate oversight. A research-only product listing is not equivalent to either an approved medicine or a patient trial.
What It Does in the Body
Early work investigated DSIP in relation to sleep and physiological regulation, but a precise clinical mechanism and dependable treatment role are not established by the cited report. It would be misleading to describe the peptide as a direct replacement for normal deep sleep or as correcting every form of disrupted sleep. For the uses discussed here, reliable clinical onset, peak benefit, and duration are not established. Route-specific human peak exposure and persistence cannot be inferred from community schedules or a laboratory response.
Benefits & Reported Experiences
The historical report described symptom improvement, not a modern large controlled assessment of insomnia remission. The study cannot establish a reliable percentage of responders or a result timeline. Persistent sleep problems can have different causes; outcomes from a selected small group may not apply to someone with another condition.
Side Effects & Risks
An uncontrolled report involving seven participants cannot characterize uncommon adverse events, interactions, or long-term safety. Sleep-related symptoms also deserve assessment because sedating or sleep-directed interventions can obscure an underlying issue. A clinician should review other medicines, substance use, and relevant medical history before considering any treatment.
Delivery Options
A route used in an old experiment does not establish equivalence for nasal sprays, oral products, or other marketed preparations. Exposure and product quality differ. This educational page provides no injection, mixing, or dosing directions and does not endorse self-administration of materials labeled only for research.
Product Quality & Storage
A trustworthy assessment separates the identity of the peptide from the quality of the finished product and from evidence of clinical benefit. Those are different questions. A laboratory certificate cannot establish an insomnia indication or replace controlled human research, even when a supplier presents detailed protocol charts. Storage must follow the authorized finished product’s labeling or an approved study protocol; temperatures and beyond-use times cannot be inferred from research-vial guidance.
Combinations & Interactions
Combining DSIP with other sleep or cognitive compounds may make drowsiness, sleep changes, and adverse events harder to interpret. Community accounts of complementary effects are not evidence of a tested combination. The small study cited here cannot validate a multi-product regimen, and no stacking schedule is provided.
Talking With Your Provider
For ongoing insomnia, discuss sleep history, daytime impairment, and possible contributing conditions with a clinician. Established sleep-focused care may provide a better-supported path. Bring questions about DSIP to that conversation, but ask what evidence and monitoring would justify an intervention rather than relying on its suggestive name.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is an option only where the particular substance, product, and prescribing pathway are lawful; a pharmacy cannot make every research compound available for patient use. Approved finished medicines may also be obtained from licensed non-compounding pharmacies.
Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.
Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.
Questions worth bringing to your appointment.
- Are there alternatives that address my goal?
- If treatment is appropriate, what monitoring and follow-up would I need?
- Could my health history or current medicines change the risks?
A clinician may recommend a different option—or no medication—after assessing your individual circumstances.
Saved discussion topics 0
Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.
Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.
Bring your curiosity. Start a conversation.
Create a free account to request review and manage purchases. Paid membership is optional. Clinical review and authorization still apply where required, and any separate service charges are shown before you agree to pay.
Create a free account ↗This educational information is free to read. Create a free account to request review of your care goals. Neither an account nor paid membership guarantees a prescription, access to the named compound or research enrollment.
Educational profile · U.S. context · October 7, 2026. This page does not provide personalized medical advice, dosing, or injection instructions.
Bring your saved topics to your care team.
Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.
Choose saved topics for review →